Bioscience
Biome Secures Purchase Order with NSLC & Delivers First Shipment
Canada’s cannabis industry is projected to reach C$22.6 billion over the coming years, according to Deloitte, driven by the legalization of recreational cannabis last year. After the landmark legislation, many licensed producers were caught off-guard by the high level of demand that quickly soaked up the available supply. These dynamics have created an opportunity for […]
FSD Pharma & Canntab Rank Among the Top 2018 Cannabis Stocks
The cannabis industry experienced significant growth last year, particularly in Canada following the legalization of adult-use cannabis on a federal level. The upcoming legalization of edible products across Canada could open the door to further growth in 2019 and beyond. Health Canada also continues to work through its backlog of licensed producer applicants to eliminate […]
WeedMD and BLOCKStrain Launch the Industry’s First Cannabis Validation Testing Program
VANCOUVER, Jan. 15, 2019 VANCOUVER, Jan. 15, 2019 /CNW/ – WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (“WeedMD”), a federally-licensed producer and distributor of medical-grade cannabis, and BLOCKSTRAIN TECHNOLOGY CORP. (the “Company” or “BLOCKStrain“) (TSXV: DNAX.V) (OTC: DNAXF) are pleased to announce that they have completed the ‘first-of-its-kind’ cannabis strain validation registration program – a testing and […]
Exclusive Interview: Lexaria CEO Discusses Progress & Plans at O’Cannabiz 2018
The O’Cannabiz Conference and Expo in Vancouver, Canada last month featured hundreds of cannabis companies from around the world this year—and CFN Media was there to film exclusive interviews with many of the leaders in the space. Lexaria Biosciences Inc. (CSE: LXX) (OTCQX: LXRP), developer of drug delivery technologies for bioactive compounds, is one of […]
Company: Lexaria Bioscience Corp. (LXRP) Category: Stock Spotlights January 8, 2019 Biotechnology company Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) revolutionary technology, DehydraTECH, alters the way that fat soluble, plant-derived molecules are absorbed into the body. A recent article further discussing the company reads, “Chemicals or intimidating complex ingredients that require disclosure on food labels are […]
FSD Pharma Completes Harvest And Passes Analytical Testing Of Second Lot
Company in position for pre-sales license inspection, last step to issuance of a Sales License – CSE: HUGE OTC: FSDDF FRA: 0K9 TORONTO, January 8, 2019 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) is pleased to announce that its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), a licensed […]
Canntab & FSD Pharma Make Cannabis More Palatable for Doctors
Cannabinoids have the potential to radically transform the pharmaceutical industry. For example, new studies suggest that cannabis legalization could reduce opioid prescriptions by about six to 12 percent. The problem is that medical cannabis is very different from pharmaceutical drugs—it’s hard for physicians to prescribe treatments that lack consistency or may be metabolized differently between […]
Pascal Biosciences Provides Year-End Investor Update and Reviews Upcoming Milestones
– 2018 pipeline expansion includes lead cannabinoid-based cancer therapeutic – Clinical trial in glioblastoma to begin in 2019 VANCOUVER, British Columbia and SEATTLE, Dec. 20, 2018 (GLOBE NEWSWIRE) — Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced a year-end review of accomplishments during 2018 and insight into plans […]
NanoSphere Closes $1.335M First Tranche of Private Placement
DENVER–(BUSINESS WIRE)–NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) the biotechnology leader behind the patented NanoSphere Delivery System™, is pleased to announce a first tranche closing of its non-brokered private placement announced November 28, 2018. Pursuant to the first tranche, the company issued 4,452,254 Units at a price of $0.30 per Unit for gross proceeds […]
How California Can Overcome Its Cannabis Challenges
California’s cannabis industry is projected to reach $5.1 billion by the end of 2019, according to BDS Analytics, but unexpected challenges have slowed progress. These challenges range from excessive regulations to sky-high taxation. Investors looking for opportunities in the state may want to look at companies that are actually working to solve these challenges rather […]
Canntab Partners with Leading Surgeon to Conduct Pain Management Trial
The opioid industry is expected to generate nearly $20 billion in annual revenue by 2020, but the addictive nature of the drug has doctors and patients increasingly concerned. With the legalization of cannabis across Canada and many U.S. states, there’s an opportunity to replace dangerous opioids with efficacious cannabinoids to treat chronic and acute pain. […]
Pascal Biosciences Announces Year-End Investor Update Webcast
Advancement of Cannabinoid Cancer Programs and Corporate Review to be Presented Scheduled for Dec. 17, 2018 at 1:30 p.m. Pacific VANCOUVER, British Columbia and SEATTLE, Dec. 10, 2018 (GLOBE NEWSWIRE) — Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, announced today it will host a year-end investor update webcast […]
Biome Grow Signs Massive Provincial Supply Agreement
Canada’s cannabis industry has charged forward full-steam following the legalization of recreational cannabis in October. While there was an initial flurry in provincial agreements, many licensed producers experienced a shortfall in their supply commitments. These dynamics encouraged many provinces to seek additional suppliers to help meet growing customer demand as Health Canada works through its […]
NanoSphere Forms Strategic Partnership to Launch Evolve Products in Mexico
VANCOUVER, British Columbia Agreement will bring the patented NanoSphere Delivery System™ to an emerging $5 billion cannabis market NanoSphere Health Sciences Inc. (CSE:NSHS) (OTC:NSHSF) (“NanoSphere” or “the Company”), the biotechnology leader behind the patented NanoSphere Delivery System™, is pleased to announce the Company has signed a Letter of Intent forming a partnership with Abba Import […]
Creso Pharma: A Truly Global Cannabis Company
The North American cannabis industry is littered with companies touting global ambitions. There are regular announcements regarding letters of intent to distribute in emerging markets like Europe and Latin America, long on potential and short on concrete details. Many of these announcements are speculative at best, requiring a mix of regulatory approvals, licensing, product development, […]
Canntab Nears Commercialization with Innovative Cannabis Tablets
The global cannabis industry is projected to reach $146.4 billion by 2025, according to Grand View Research, representing a blistering 34.6 percent compound annual growth rate. With medical and adult-use legalization across a growing number of countries, there’s an enormous opportunity for innovative companies to become established market leaders and patients to access new life-changing […]
AREV Builds an Industry-Leading Cannabis Topicals Portfolio
The global skincare and dermatology market is projected to grow from $20 billion in 2015 to $33.7 billion by 2022, according to GBI Research, representing a 7.73 percent compound annual growth rate. While premium biologics have become a popular treatment category, the legalization of cannabis has opened the door to the benefits of cannabinoids and […]
Halo Labs: Improving Investor Reach, Transparency, and Liquidity
The cannabis industry has rapidly evolved over the past year. In addition to the federal legalization of adult-use cannabis in Canada, the United States’ midterm elections could foretell a shift in federal policy over the coming months. Investors have many different options when looking for exposure to the industry, but it’s important to look at […]
Lexaria Targets Cannabinoids, Tobacco, Hemp, and Pharma Markets with New Subsidiaries
The cannabis industry is projected to generation hundreds of billions of dollars of revenue over the coming years, driven by the legalization of medical and recreational cannabis across North America. While many investors are focused on cultivation or dispensary operations, drug delivery technologies may represent an even bigger opportunity. These companies have an opportunity to […]
NexTech AR Brings Augmented Reality to Cannabis
The cannabis industry is projected to surpass $75 billion by 2030, according to Cowen & Co., driven by the legalization of both medical and adult-use marijuana. While just over half of Americans have used cannabis at some point in their life, cannabis companies face an uphill battle educating those that haven’t recently tried cannabis about […]
Gabriella’s Kitchen Is Redefining The Cannabis Health and Wellness Industry
Gabriella’s Kitchen (CSE: GABY), the award-winning consumer packaged goods company whose array of super-nutritional foods are currently sold in more than 3,400 stores across North America, is launching a revolutionary new line of cannabis infused nutritional edibles. The expansion as well as a number of announced acquisitions has positioned the company on the cutting edge […]
CALGARY and SANTA ROSA, CA, Nov. 9, 2018 /CNW/ – Gabriella’s Kitchen Inc. (the “Company” or “GABY”) (CSE: GABY) today provided comments to shareholders on recent changes in United States cannabis regulations, plus other national and international developments in the cannabis sector. GABY commented to shareholders today on recent draft regulations that have been released by the […]
CFN Media’s Exclusive Interview with Pascal Biosciences
The cannabis industry is projected to reach $75 billion by 2030, according to Cowen & Co., driven by the legalization of medical and recreational cannabis across a growing number of states. While many investors are familiar with cultivators and dispensaries, there could be an even greater opportunity on the medical side of the industry. Cannabinoids […]
The Crucial Role of Genetics in the Future of the Cannabis Industry
The history of the legal cannabis industry is fairly short, a work in progress. The legal market is only beginning to leave behind its black market origins, and the prohibition on scientific research around the plant is being lifted. One fact that has recently come to light is that a particular strain of cannabis can […]
VANCOUVER, British Columbia and SEATTLE, Nov. 05, 2018 (GLOBE NEWSWIRE) — Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the peer reviewed publication and upcoming presentation of their recently licensed cannabinoid-derived drug program for glioblastoma. Dr. Stella and colleagues are publishing their work today in the European […]
Leading-edge cannabis wellness company brings new cannabis-infused products to California CALGARY, Nov. 2, 2018 /CNW/ – Gabriella’s Kitchen Inc. (“GABY” or the “Company“) (CSE: GABY), an innovative and leading-edge cannabis wellness company, is pleased to announce that its alto™ brand of cannabis infused products (“Infused Products”) have launched in Northern California. GABY offers a variety […]
CannabisNewsAudio announces the Audio Press Release (APR) titled “Canada Leads International Cannabis Boom – and It’s Not About Smoking,” featuring Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP). To hear the CannabisNewsAudio version, visit: http://cnw.fm/7n7B5 To read the full editorial, visit: http://cnw.fm/6sImP After much political maneuvering, recreational cannabis is now legal in Canada in keeping with […]
Pascal Biosciences: Cannabinoids Could Play a Role in Destroying Cancer Cells
Cannabinoids have been widely used in oncology for nausea, appetite stimulation, and pain reduction in patients undergoing chemotherapy, but some researchers believe that they could play a more active role in combating the disease. While cannabis hasn’t been shown to cure cancer on its own, despite the pervasiveness of anecdotal stories, scientists have found that […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matthew Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion to creating strategic alliances. He has breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. In 2005, Mr. Nordgren received his education at the University […]
Tom Zuber is Zuber Lawler & Del Duca’s Managing Partner. He has a degree with highest honors in biomedical engineering and has advised some of the most iconic companies in the world on their patent and trademark portfolios. He is at the cutting edge of cannabis patent and trademark law. He holds degrees from Harvard University and Columbia Law […]
Hempsana Inc. is a Canadian cannabis company specializing in cannabis derivatives with focus on Extraction & Purification, End-Product Manufacturing and Testing.
3Sixty is one of Canada’s leading security service providers to the cannabis sector.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
